Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather uneventful. The subsequent CMD however provided interesting insights into how Nanexa have learned to mitigate skin reactions at the injection site (that forced NEX-18 back into preclinical development back in 2021) and the current pipeline of partner projects where monoclonal antibodies now account for half of partner pipeline. It also provided a welcome reminder of how fast the 505b-path (for new or modified versions of previously approved drugs) to approval can be (where Phase I in 505b can compare roughly to Phase III for a New Chemical Entity). We now look forward to start of Phase I with NEX-22, hopefully before summer, as well as the outcome of the partner project with Novo Nordisk and other advanced evaluation projects. All in all, we continue to find support for a fair value of SEK 2.6-9.9 per share.

https://www.emergers.se/nanexa_v24/

Emergers